pipeline

Zymeworks Inc . (NYSE: NASDAQ:) reported its financial results for the third quarter of 2024, revealing a net loss of $99.2 million, which is a slight improvement from the $104.2 million loss in the same period last year. The company, which specializes in the development of innovative cancer treatments, has…

Innate Pharma (Euronext Paris: IPH) has presented its first-half 2024 financial results and clinical pipeline updates in an earnings call held in October 2023. The company, which is currently without a permanent CEO, reported advancements in its oncology-focused drug development, including the orphan drug designated lacutamab, and a robust pipeline…